Welcome to our dedicated page for Ironwood Pharmaceuticals - news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals - stock.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a biopharmaceutical company dedicated to creating innovative medicines that significantly improve the lives of patients. Founded in 1998, Ironwood specializes in gastrointestinal (GI) therapeutics and has a strong focus on developing and commercializing treatments for chronic conditions of the GI tract.
The company's flagship product is a medicine designed for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This medicine, discovered and developed by Ironwood, is now fully commercialized and widely used to alleviate symptoms in patients, improving their quality of life.
Ironwood's research pipeline is robust, with multiple investigational medicines targeting both the upper and lower GI tract. The company leverages its expertise in gastrointestinal disorders and pharmacologic expertise in guanylate cyclases to develop new therapies that address unmet medical needs.
Beyond its core product, Ironwood is actively exploring new opportunities and expanding its portfolio through collaborative licenses, commercial agreements, and strategic acquisitions. These efforts aim to enhance the company's research, development, manufacturing, and marketing capabilities, thereby driving growth and innovation.
Recent achievements for Ironwood include the advancement of several clinical trials, promising data from ongoing research studies, and strategic partnerships aimed at enhancing product development and market reach. Financially, Ironwood continues to build value, achieving milestones that attract continued support from shareholders.
Ironwood Pharmaceuticals remains committed to its mission of making a difference for patients through the development of groundbreaking therapies. The company’s strong pipeline, dedicated team, and strategic initiatives position it as a leading player in the field of gastrointestinal therapeutics.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) reported positive Phase III results for apraglutide in adult patients with SBS-IF and explored SR GI aGVHD. LINZESS EUTRx demand grew by 10% YoY. FY 2024 guidance revised due to LINZESS gross-to-net change. Financial highlights include total revenue of $74.9 million, GAAP net loss of $4.2 million, and adjusted EBITDA of $12.8 million.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The management will engage in a fireside chat at 10:00 a.m. ET at the New York Hilton Midtown. The event will be live streamed on the company's website. A replay will be available for 1 year.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will present new data on once-weekly apraglutide in short bowel syndrome with intestinal failure (SBS-IF) at the 2024 Digestive Disease Week®. The pivotal Phase III STARS study's findings and the STARS Nutrition Study will be highlighted, alongside additional posters focusing on linaclotide, irritable bowel syndrome, and functional constipation. Apraglutide data from the STARS trial aims to reduce parenteral support (PS) dependency in adult SBS-IF patients, with plans for a new drug application submission to the FDA.
FAQ
What is the current stock price of Ironwood Pharmaceuticals - (IRWD)?
What is the market cap of Ironwood Pharmaceuticals - (IRWD)?
What does Ironwood Pharmaceuticals specialize in?
What is Ironwood's flagship product?
When was Ironwood Pharmaceuticals founded?
What are some of Ironwood's recent achievements?
How does Ironwood plan to expand its research and development capabilities?
What areas does Ironwood's research pipeline target?
What other conditions, besides IBS-C and CIC, is Ironwood working on?
How does Ironwood build value for its shareholders?
Where is Ironwood Pharmaceuticals listed?
What is the company's mission?
